Phase IV trial in 195 RA patients in sustained remission on bDMARDs: dose reduction did not meet non-inferiority vs standard care for 12-month joint flare (22.7% vs 17.2%); adverse events did not differ significantly.
RCTn = 195
Blanco et al. Clinical and molecular data to predict flares in DMARD optimization in rheumatoid arthritis: a randomized, controlled, open-label, non-inferiority trial